Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
70.61
-3.25 (-4.40%)
At close: Dec 12, 2025, 4:00 PM EST
70.40
-0.21 (-0.30%)
After-hours: Dec 12, 2025, 7:59 PM EST
Tempus AI Revenue
Tempus AI had revenue of $334.21M in the quarter ending September 30, 2025, with 84.72% growth. This brings the company's revenue in the last twelve months to $1.11B, up 72.58% year-over-year. In the year 2024, Tempus AI had annual revenue of $693.40M with 30.38% growth.
Revenue (ttm)
$1.11B
Revenue Growth
+72.58%
P/S Ratio
11.46
Revenue / Employee
$460,524
Employees
2,400
Market Cap
12.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 693.40M | 161.58M | 30.38% |
| Dec 31, 2023 | 531.82M | 211.15M | 65.85% |
| Dec 31, 2022 | 320.67M | 62.82M | 24.36% |
| Dec 31, 2021 | 257.85M | 69.85M | 37.15% |
| Dec 31, 2020 | 188.00M | 125.95M | 202.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TEM News
- 3 days ago - Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
- 3 days ago - Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium - Business Wire
- 7 days ago - Is Tempus AI the Next Big Artificial Intelligence Stock to Buy? - The Motley Fool
- 9 days ago - Tempus AI, Inc. (TEM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript - Seeking Alpha
- 14 days ago - Why Tempus AI Stock Soared This Week - The Motley Fool
- 24 days ago - Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference - Business Wire
- 27 days ago - Tempus AI: Opportunity To Build Position - Seeking Alpha
- 4 weeks ago - Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research - Business Wire